Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions
2.3.2026 07:30:00 CET | Business Wire | Press Release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership Agreement to collaborate on the development of integrated solutions aimed at improving 4G and 5G coverage across challenging indoor and outdoor environments.
The agreement establishes a structured framework for Airgain and Nextivity to jointly define and co-develop integrated coverage solutions that leverage Airgain’s Lighthouse™ 5G Intelligent Node platform and Nextivity’s GO family of intelligent repeaters powered by Nextivity’s IntelliBoost® processor to enhance 4G and 5G coverage solutions beyond the walls of a building.
Large Market Opportunity & Accelerated Go‑to‑Market Execution
Industry demand for intelligent 4G and 5G coverage-extension solutions continues to accelerate as operators, enterprises, and public safety organizations expand network densification and broader 5G deployment. Mid-band 5G rollouts, in particular, are driving the need for more scalable and cost-efficient coverage architectures as networks evolve to serve larger areas and more demanding applications. This collaboration supports rising customer requirements for seamless 4G and 5G connectivity across enterprise, venue, campus, and extended outdoor environments, enabling more efficient coverage expansion compared to traditional macro‑based approaches.
This strategic partnership positions Airgain and Nextivity to provide site-wide comprehensive coverage solutions to a large and rapidly expanding market that includes a growing number of mixed-use / indoor-outdoor sites. By aligning complementary technologies, we are strengthening the companies’ collective reach and impact across operator and infrastructure channels.
“This partnership establishes a path for combining Airgain’s smart beam forming antenna systems and Lighthouse™ 5G Intelligent Node platform with Nextivity’s intelligent coverage technologies,” said Dr. Ali Sadri, Chief Technology Officer of Airgain. “Together, we are driving the development of integrated systems to extend 4G and 5G coverage across complex indoor and outdoor environments.”
“Nextivity has built a global reputation for delivering high-performance, intelligent cellular coverage systems in partnership with Mobile Network Operators,” said Dr. Michiel Lotter, Chief Executive Officer of Nextivity. “This strategic partnership with Airgain positions both companies to address an expanding set of customer coverage requirements that extend into outdoor environments. We’re excited about the broader opportunities this collaboration creates for both companies.”
Joint Industry Engagement at MWC Barcelona
Airgain and Nextivity will both be present at MWC Barcelona, March 2nd - 6th, 2026, where the companies will meet with operator customers, channel partners, and ecosystem collaborators to discuss the strategic partnership and explore emerging applications for next-generation 4G and 5G coverage solutions
- Meet with Airgain: Booth 2J19MR
- Meet with Nextivity: Room 7B26Ex
Both companies will host scheduled partner briefings and roadmap discussions throughout the event.
About Airgain, Inc.
Headquartered in San Diego, California, Airgain Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions that drive cutting-edge innovation in 5G technology. We are committed to delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. For more information, visit www.airgain.com, or follow us on LinkedIn and X.
About Nextivity
Nextivity® makes the world’s most intelligent, powerful, and easy-to-use public safety, cellular and private 5G coverage solutions. Our SHIELD public safety and CEL-FI cellular signal booster products use proprietary IntelliBoost® technology and support IoT sensing - pairing unbeatable signal coverage with the ability to Do More with DAS.
Airgain, AirgainConnect, Lighthouse, and the Airgain logo are trademarks or registered trademarks of Airgain, Inc. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260301858530/en/
Contacts
Media Contact:
Lynn Robertson
PR@airgain.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom